Plain-English translation of NCT06567717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and — two supplements that may help reduce inflammation and support lung health — can slow the progression of idiopathic pulmonary fibrosis. You would take the medication along with your regular IPF treatments. The study also wants to see if this type of research can be done remotely, so you can participate from home with video visits and local lab work.
Idiopathic pulmonary fibrosis causes scarring in the lungs that gets worse over time, making it harder to breathe. Doctors want to find new ways to slow this scarring, and early research suggests this medication might help by reducing inflammation in lung tissue.
You likely qualify if…
You likely don't qualify if…
You would take the medication or placebo daily for 24 weeks while continuing your regular IPF care with your own doctor. Most visits would happen by video conference at home, but you would have blood work done either at home or at a local lab. You would also have lung function tests and imaging scans every 12 weeks as part of your regular care. The entire study lasts about one year.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States